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Abstract
Background The presence of lymph node (LN) metastasis is a critical prognostic factor in colorectal cancer (CRC) patients 
and is also an indicator for adjuvant chemotherapy. The gold standard (GS) technique for LN diagnosis and staging is based 
on the analysis of haematoxylin and eosin (H&E)-stained slides, but its sensitivity is low. As a result, patients may not be 
properly diagnosed and some may have local recurrence or distant metastases after curative-intent surgery. Many of these 
diagnostic and treatment problems could be avoided if the one-step nucleic acid amplification assay (OSNA) was used rather 
than the GS technique. OSNA is a fast, automated, standardised, highly sensitive, quantitative technique for detecting LN 
metastases.
Objectives The aim of this study was to assess the budget impact of introducing OSNA LN analysis in early-stage CRC 
patients in the Spanish National Health System (NHS).
Methods A budget impact analysis comparing two scenarios (GS vs. OSNA) was developed within the Spanish NHS frame-
work over a 3-year time frame (2017–2019). The patient population consisted of newly diagnosed CRC patients undergoing 
surgical treatment, and the following costs were included: initial surgery, pathological diagnosis, staging, follow-up expenses, 
systemic treatment and surgery after recurrence. One- and two-way sensitivity analyses were performed.
Results Using OSNA instead of the GS would have saved €1,509,182, €6,854,501 and €10,814,082 during the first, second 
and third years of the analysis, respectively, because patients incur additional costs in later years, leading to savings of more 
than €19 million for the NHS over the 3-year time horizon.
Conclusions Introducing OSNA in CRC LN analysis may represent not only an economic benefit for the NHS but also a 
clinical benefit for CRC patients since a more accurate staging could be performed, thus avoiding unnecessary treatments.
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1 Introduction
Colorectal cancer (CRC) is the third most common cancer 
worldwide, with nearly 1.8 million newly diagnosed cases in 
2018, according to Globocan 2018 estimates [1]. In Spain, 
CRC was the most prevalent type of cancer in 2017, with 
34,331 new cases diagnosed that year, and was the second 
leading cause of death by cancer in 2016 [2]. Over the last 
30 years, improvements in early diagnosis and treatment 
have doubled the 5-year survival of CRC patients [3–6]; 
however, these improved outcomes have been costly and 
imposed a higher economic burden on health systems [7]. 
In 2016, the mean cost per CRC patient in Spain ranged 
from €9634 among in situ tumours to €41,550 for stage III 
patients. Over this same period, the global mean cost per 
patient was €28,741 [7].
Unless there are other factors that hinder the surgical 
procedure, surgical excision is the main approach for non-
disseminated CRC [8]. The presence of lymph node (LN) 
metastasis is a critical prognostic factor for patients with 
CRC, and also determines the need for adjuvant chemother-
apy treatment [9]. Pathological LN staging is considered 
the gold standard (GS), based on the evaluation of routine 
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Key Points for Decision Makers 
Lymph node (LN) staging is based on conventional gold-
standard pathology, which analyses  < 1% of the LN.
LN micrometastases may not be detected by haematoxy-
lin and eosin due to tumour allocation bias, and may 
cause tumour recurrences.
A more accurate LN staging using the one-step nucleic 
acid amplification molecular assay could allow a better 
patient management, and only patients at risk of recur-
rence would be treated. Savings per patient in unneeded 
procedures and chemotherapy treatments stretch over the 
years, and may represent an important economic benefit 
for the National Health Service.
independently of the pathologic pN stage and other prog-
nostic factors. In breast cancer, the total tumour load has 
become a predictive factor for progression. It is related to 
patient outcome and has become a tool for patient manage-
ment and decision making [24].
One of the innovative aspects of OSNA is that, unlike 
the GS technique, OSNA can analyse the whole LN in a 
short time frame, and in an automatic and standardised way 
[22]. OSNA is already being used for intraoperative senti-
nel LN diagnosis in breast carcinoma [23], and has been 
demonstrated to be a time-efficient tool with standardised 
assessment of LNs [19]. A CRC meta-analysis including five 
studies compared the cut-off point of OSNA versus the GS 
and demonstrated an average sensitivity of 89.4% and speci-
ficity of 93.3% [19]. In addition, the OSNA assay is faster 
than the GS technique; OSNA takes 30–40 min to analyse 
all LNs from two patients, compared with the several hours 
required for GS analysis [18].
In breast cancer, Saruta and Puig-Junoy estimated savings 
of US$346 per patient over a 5-year period when OSNA was 
used intraoperatively instead of conventional intraoperative 
sentinel LN biopsy [25]. The National Institute for Health 
and Care Excellence (NICE) assessed OSNA for CRC 
staging and estimated an average cost per patient (includ-
ing capital, maintenance, and disposable costs) of between 
£568 and £608 (excluding value-added tax), depending on 
the cost of disposables (re-agents and consumables) [22]. 
Nevertheless, budget impact studies of OSNA for CRC stag-
ing are lacking, highlighting the need for economic evalua-
tions assessing OSNA in this patient population. The present 
study performed a budget impact analysis of OSNA in CRC 
patients in Spain, comparing two scenarios—GS and OSNA.
2  Materials and Methods
2.1  Perspective and Time Horizon
A ‘what-if’ budget impact analysis of introducing OSNA 
to perform LN analysis in CRC patients in the Spanish 
National Health System (NHS) was developed using the 
SensIt program (a sensitivity analysis add-in for  Microsoft® 
Excel 2007–2013 [Microsoft Corporation, Redmond, WA, 
USA]). The analysis was performed from the NHS perspec-
tive. Costs were calculated annually, corresponding to the 
number of patients newly diagnosed with CRC undergoing 
surgery during the first year, over a 3-year time horizon from 
2017 to 2019. As recommended in budget impact analyses 
by the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) [26] and by a Spanish phar-
macoeconomic guideline [27], costs were not discounted. 
This analysis follows the ISPOR principles of Good Practice 
Framework [26].
haemotoxylin and eosin (H&E)-stained slides; however, 
evidence indicates that it is not the best methodology of 
LN staging [10–13]. Significant limitations of this technique 
are its low sensitivity, since only a small part of the LN is 
examined [10, 14–18], and the fact that it is a morphology-
based analysis [19]. The American Joint Committee on Can-
cer established that at least 12 LNs should be analysed to 
assure a reliable pathologic pN0 assessment [20]. Therefore, 
undetected metastases within the unsampled material may 
be the cause of an increased risk of local recurrence and/or 
distant metastases after curative-intent surgery [19]. Yama-
moto et al. reported that 6 of 83 OSNA-positive LNs were 
diagnosed as negative by H&E and immunohistochemical 
staining (7.2%) [9]. Other studies report that local recur-
rence or distant metastases occur in between 10 and 30% 
of CRC patients after surgical tumour resection [6, 14, 16, 
18]. Moreover, stage II CRC patients with occult LN metas-
tasis are considered a high-risk group for disease recurrence 
[15], and between 10 and 25% of these patients die from 
disease [6, 21]. Therefore, missed LN metastases with the 
GS method might cause disease understaging, leading to the 
undertreatment of patients [19].
An innovative technique called one-step nucleic acid 
amplification assay (OSNA) has been introduced in some 
hospitals in Europe and within the Asia-Pacific region 
for detecting LN metastases in patients with breast can-
cer. OSNA is a quantitative in vitro diagnostic molecular 
assay system, designed to measure the amount of tumoural 
cytokeratin 19 (CK19) messenger RNA (mRNA) within 
LNs [9, 22]. With OSNA, the LN total tumour burden or 
total tumour load is defined as the sum of all CK19 mRNA 
copies present in all dissected LNs of a given case [15, 23]. 
The total tumour load has already been implemented in 
routine clinical practice for breast cancer patients, allow-
ing patients to be classified into low- and high-risk groups, 
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2.2  Features of the Spanish Health Care System
The Spanish NHS is a decentralised system covering 17 
Spanish regions [28]. Medical procedures, tests and drugs 
administered in the hospital setting are totally covered by 
the Spanish health services. In Spain, medical devices are 
normally acquired by tendering procedures.
2.3  Eligible Population
The cohort of patients included in the present analysis com-
prised Spanish patients diagnosed with CRC who underwent 
curative-intent surgical excision. Inclusion criteria were 
patients over 18 years of age with primary histologically 
confirmed colon carcinoma and positive CK19 immunohis-
tochemistry. Exclusion criteria were based mainly on techni-
cal reasons, i.e., open colectomies were excluded due to the 
risk of CK19 contamination from normal mucosa to LNs 
that did not contain CK19. Surgical specimens that were 
fixed in formalin were also excluded since the OSNA assay 
must be performed on fresh tissue. Rectal tumours treated 
with neoadjuvant therapy were excluded for the intrinsic dif-
ficulty of LN dissection after therapy. Cases with extensive 
fat infiltration were excluded since LNs cannot be identified 
and dissected in the middle of primary infiltrating tumour. 
The analysis was performed based on the estimated patient 
subgroups according to the recruitment performed by Rak-
islova et al. regarding systemic therapy (ST) administration 
[18].
The patient cohort included in the study was obtained 
from Globocan data (34,331 estimated new cases of CRC 
in Spain) [29], taking into account that 70.7% of patients 
diagnosed with CRC will undergo surgery, as reported by 
Corral et al. [7]. In our study, the target population was fur-
ther reduced, and only 74.1% of surgically treated patients 
could be included for LN OSNA analysis once the exclusion 
criteria detailed above were applied. The size of the target 
population was assumed to be constant over the 3-year time 
horizon.
2.4  Interventions
Clinical schemes used to populate the model follow CRC 
National Comprehensive Cancer Network (NCCN) guide-
lines [20], which are in line with Spanish clinical practice 
(Fig. 1). The treatment of choice for stage 0, I, II, or III 
CRC patients is surgical excision. After surgery, depending 
on tumour (pT) and LN status (pN) stage, some patients 
were treated with ST, consisting of different chemotherapy 
(QT) regimens [30–37]. LN analysis performed using the 
GS technique implies a risk of misdiagnoses, leading to 
undertreatment. Undertreated patients may have a higher 
risk for disease recurrence. According to guidelines, patients 
showing CRC recurrence might be treated with ST and/or 
surgery. ST after recurrence consists of QT regimens, which 
can include biological agents. The OSNA assay detection 
starts at 250 copies/µL, below 250 copies it is considered 
negative, allowing the selection of those patients who will 
very unlikely have tumoural cells in their LNs. However, the 
OSNA values and the clinical significance do not exactly 
correlate, and the presence of OSNA positivity does not 
imply a negative biological effect or patient recurrence by 
itself. A cut-off of 7500 copies/µL has been found to be 
related to a higher risk of recurrence and worse prognosis 
[19, 38]. Therefore, the threshold used in this study was 
7500 copies/µL; OSNA values ≥ 7500/µL should be con-
sidered a positive result.
2.5  Scenarios and Model Description
The model compares a reference scenario versus a test sce-
nario over a 3-year time horizon. The reference scenario 
assesses the management cost of CRC patients whose LNs 
have been analysed using the GS technique (H&E staining), 
while the test scenario estimates the management cost of 
CRC patients if LN analysis had been performed using the 
OSNA technique in the Spanish NHS framework (Fig. 1). 
Incident patients diagnosed during the first year of the analy-
sis would be followed over the 3-year time horizon in order 
to collect costs associated with CRC disease.
The proportion of patients with positive or negative LNs, 
and the proportion of patients receiving ST after a positive 
or negative LN analysis, differs between scenarios (Fig. 1). 
In the reference scenario, 78.79% of patients showed nega-
tive LNs using the GS technique [18], of which 15.99% were 
treated with ST according to data obtained from three differ-
ent studies [39–41]. Some negative LN patients were treated 
based on decisions taken on multidisciplinary committees 
or recommendations made by clinical guidelines such as the 
NCCN.
In the reference scenario, 77.32% of patients with positive 
LNs by GS received ST [39, 41]. The model assumes that 
all patients with negative LNs analysed using the OSNA 
technique (86.47%) would not receive ST, while 77.32% of 
patients with a positive OSNA result (cut-off of > 7500 cop-
ies/µL; 13.53%) would be treated with ST. Patients with no 
ST would enter the follow-up period after surgery, while 
patients receiving ST would enter the follow-up period 
after adjuvant treatment. During the first year of follow-
up, 98.10% and 98.82% of patients in the reference and 
test scenarios, underwent and would undergo, respectively, 
colonoscopies, medical visits, blood tests (including moni-
toring of carcinoembryonic antigen; CEA) and computed 
tomography (CT) scans. The proportion of patients using 
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the latter healthcare resources in the reference and test sce-
narios would be 96.21% and 97.64%, respectively, during the 
second year, and 92.42% and 95.29%, respectively, during 
the third year. The frequency of tests and visits is described 
in Table 1.
The percentage of patients with recurrence was obtained 
from a recently published study comparing GS and OSNA 
over a 2-year period [18]. Recurrence rates observed by Rak-
islova et al. [18] during the 2-year period are assumed to 
be maintained during the third year of the analysis for both 
the GS and OSNA techniques. In both scenarios, 42.68% 
of recurrent patients underwent surgery for recurrence and 
83.73% received ST for recurrence each year of the analysis 
[40].
2.6  Input Data
Assumed parameter values for all clinical and cost data 
for both scenarios are shown in Table 1, and the strengths, 
weaknesses and potential data biases are described in elec-
tronic supplementary Table S1. We conducted a search of 
the Pubmed and eSalud electronic databases using different 
combinations of keywords, such as ‘OSNA’, ‘colorectal can-
cer’, ‘National Health System’ and ‘costs’. Data credibility 
was assessed as described in the data extraction protocol 
(electronic supplementary Table S2).
2.7  Costs
The present analysis only includes direct costs from 2017, 
with all costs given in Euros (€). Drug costs were calculated 
based on the ex-factory price (PVL, Spanish acronym for 
Precio de Venta del Laboratorio) [42]. Daily defined doses 
were obtained from the summary of product characteris-
tics of each drug, and from clinical trials if not specified in 
the summary of product characteristics. The daily dose per 
patient was calculated considering an average weight and 
height of 70.2 kg and 166 cm, respectively [43]. Regarding 
drugs administered intravenously, vial wastage was assumed. 
The cost of ST following first surgery is the average cost of 
the common QT regimens used in clinical practice, and the 
cost of ST after recurrence is an average value of the cost of 
the QT regimens and biological agents (Table 2). An outlier 
detection technique was used when calculating the average 
cost of ST, excluding those QT regimens with an annual 
cost under the average cost divided by two. The cost of other 
health resources used, such as medical visits and tests, were 
obtained from the Spanish health costs database [44].
Fig. 1  Budget impact scenarios. 
CEA carcinoembryonic antigen, 
CT computed tomography, € 
Euros, GS gold standard, OSNA 
one-step nucleic acid amplifica-
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2.8  Sensitivity Analyses
A one-way sensitivity analysis (OWSA) was performed in 
order to assess the uncertainty and robustness of the model. 
Clinical and cost parameters were increased and decreased 
according to the minimum and maximum values shown in 
Table 1, which were mostly obtained from the literature. For 
the purposes of sensitivity analyses, the lowest (Vanuatu) 
and highest (China) number of possible incident patients 
worldwide was considered [29].
Table 1  Inputs used for the 
base-case and sensitivity 
analyses
CEA carcinoembryonic antigen, CRC colorectal cancer, CT computed tomography, GS gold standard, N 
number of patients, OSNA one-step nucleic acid amplification assay, ST systemic therapy, € Euros
a Refers to the overall recurrence rate during the first year in both scenarios, independently of the results 
obtained
b Data provided by the manufacturer
Parameters Inputs References Range (lowest–highest)
CRC incidence (N) 34,331 [54] 10–521,490
Lymph node (N) 15.00 [55] 10.00–27.00
GS-negative (%) 78.79 [9, 18, 39] 66.14–100
GS-positive (%) 21.21 [9, 16, 18] 0.00–33.89
GS-negative, no ST (%) 84.01 [39–41] 79.69–100
GS-negative, ST (%) 15.99 [9, 39, 40] 12.20–20.30
GS-positive, ST (%) 77.32 [9, 39] 62.64–92.00
OSNA-negative (%) 86.47 [16, 18] 61.27–100
OSNA-positive (%) 13.53 [16, 18] 0.00–33.85
OSNA-negative, no ST (%) 100.00 [20] 79.69–100.00
OSNA-positive, ST (%) 77.32 [39, 40] 62.64–92.00
Recurrence GS-negative (%) 1.92 [18, 56] 0.00–1.92
Recurrence GS-positive (%) 28.57 [18, 56] 0.00–28.57
ST for recurrence GS (%) 83.73 [40] 0.00–100.00
Surgery for recurrence GS (%) 42.68 [40] 0.00–100.00
Recurrence OSNA-negative (%) 1.36 [18, 56] 0.00–1.36
Recurrence OSNA-positive (%) 26.09 [18, 56] 0.00–26.09
ST for recurrence OSNA (%) 83.73 [40] 0.00–100.00
Surgery for recurrence OSNA (%) 42.68 [40] 0.00–100.00
Recurrence GS (%)a 3.79 [18] 0.00–7.58
Recurrence OSNA (%)a 2.36 [18] 0.00–4.71
Hospitalisation days (N) 7.00 [57] 1–14
Blood test, CEA, visits (N) 4.00 [20] 2.00–8.00
Abdominal CT (N) 1.00 [20] 1.00–3.00
Thoracoabdominal CT (N) 1.00 [20] 0.00–2.00
Colonoscopy (N) 1.00 [20] 0.00–2.00
Surgery after diagnosis (€) 2804.00 [44] 1402.00–5608.00
GS (cost per lymph node; €) 10.00 [44] 5.00–20.00
OSNA (cost per patient; €) 500.00 [58]b 250–700
Hospitalisation daily cost (€) 347.00 [44] 112.00–582.00
ST after first surgery (€) 2293.66 [20, 42, 43, 56, 59–65] 687.91–3739.75
Colonoscopy (€) 235.51 [44] 120.00–285.00
CEA (€) 29.00 [44] 20.00–38.00
Blood test (€) 99.19 [44] 46.78–184.89
Thoracoabdominal (€) 134.33 [44] 73.00–165.00
Abdominal CT (€) 135.00 [44] 62.00–168.00
Medical visit (€) 26.57 [44] 21.60–29.88
ST after recurrence (€) 21,966.71 [20, 42, 43, 59–73] 687.91–32,538.31
Surgery for recurrence (€) 5937.00 [44] 5038.00–7252.00
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In addition, a two-way sensitivity analysis (TWSA) was 
performed to further assess the uncertainty regarding those 
clinical parameters that were correlated and should be simul-
taneously varied; varying them independently may show 
misleading results: ‘positivity of GS vs. OSNA’, ‘recur-
rence in follow-up: GS vs. OSNA’, ‘recurrence in ST: GS 
vs. OSNA’ and ‘ST after recurrence with GS vs. OSNA’.
3  Results
3.1  Target Population
The number of patients diagnosed with CRC who underwent 
surgery was estimated as 24,265 per year, of which 17,980 
would be eligible for OSNA. In the reference scenario, 5214 
patients would receive ST after surgery, whereas in the test 
scenario, only OSNA-positive patients (1615) would receive 
ST after surgery. More patients in the reference scenario 
(1362) recurred than in the test scenario (727), and, after 
recurrence, fewer patients in the test scenario would undergo 
surgery (310 vs. 581) and receive ST compared with the 
reference scenario (608 vs. 1140).
3.2  Budget Impact After the Introduction 
of the One‑Step Nucleic Amplification 
Technique
The overall cost of the reference scenario for the first, second 
and third years was estimated at €182,711,803, €52,101,734 
and €62,878,813, respectively, while in the test scenario, 
the overall cost for the first, second and third years was 
€181,202,621, €45,247,233 and €52,064,732, respectively. 
From these results, the corresponding savings were esti-
mated to be €1,509,182 in year 1, €6,854,501 in year 2, and 
€10,814,082 in year 3, corresponding to savings of 0.002%, 
0.010% and 0.016% in the Spanish public health expenditure 
in 2014 (€66,826 million) [45]. Therefore, the introduction 
of OSNA in Spanish clinical practice for performing LN 
analysis from CRC surgical specimens could lead to an over-
all cost saving of €19,177,765 for the Spanish NHS over a 
3-year time horizon (Table 3).
The overall cost per patient using the GS or OSNA tech-
niques is estimated to be €13,193 and €12,126, respectively. 
Therefore, cost savings of €1067 per patient for the next 
3 years after CRC diagnosis are achievable if the OSNA 
technique replaced the GS technique in the Spanish NHS.
3.3  Sensitivity Analyses
Results obtained from the OWSA and TWSA show the 
robustness of the analysis performed and confirm the results 
obtained (Figs. 2, 3, respectively). The parameters with a 
higher impact on the results are those relating to the propor-
tion of patients with negative results, using both the GS and 
OSNA techniques, and the treatment cost after diagnosis and 
recurrence. The results obtained by reducing and increas-
ing the parameters included in the analysis are in line with 
the base-case results, therefore generating savings for the 
Spanish NHS if OSNA was introduced in clinical practice 
(Fig. 2). Figure 3 shows that in each of the four analyses, the 
base case is located within the area under the line, where 
savings for the NHS would be expected. Lines drawn in 
Fig. 3 show simultaneous variations of the two parameters 
included in each analysis. 
4  Discussion
This study focuses on a novel way of assessing the economic 
impact of the use of OSNA instead of the traditional GS 
technique for CRC patients in Spain. Our results indicate 
that the Spanish NHS would have saved over €19 million 
from 2017 to 2019 if OSNA had been introduced in clini-
cal practice for surgically treated CRC patients. Savings are 
explained by the fact that OSNA ensures a more accurate 
diagnosis in CRC patients, allowing a reduction in treat-
ment costs after initial surgery, as well as costs of adjuvant 
treatments and surgery after recurrence, compared with GS 
techniques. Although patients’ LN staging is more expen-
sive with OSNA than with GS, savings regarding treatment 
costs after surgery and treatment costs due to recurrence 
are high enough to make a return on the investment made 
by the incorporation of OSNA at the diagnostic stage. Sav-
ings have already been observed during the first year, and 
increase during the second and third years of the analysis. 
Sensitivity analyses showed the robustness of the analysis. 
The number of incident patients is the variable showing a 
higher impact on the result in the OWSA (the higher the 
patient population, the greater the savings for the NHS). 
According to Globocan data [29], the countries reporting the 
lowest and highest crude incidence rate for CRC are Gambia 
and Japan, respectively. If these incidence rates were applied 
to the Spanish population, the number of incidence cases 
per year would be approximately between 238 and 54,404.
A previous study performed with breast cancer patients 
in Japan over a 5-year time horizon showed that the use of 
OSNA would lead to relevant Japanese healthcare savings 
of approximately US$121,877,910 [25]. In addition to the 
difference of diagnosis, treatment and follow-up, the influ-
ence of pathological nodal staging on treatment decision 
in breast cancer and CRC is different. In CRC, the aim is 
to pursue those cases at risk of recurrence, while in breast 
carcinoma, a surgical decision of performing lymphadenec-
tomy is undertaken, which does not depend on pathological 
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Table 2  Systemic treatments considered following the first surgery and after recurrence
Molecule Dose per cycle No. of cycles 
per year
Cost per cycle (€) Annual cost (€)
ST following first surgery; clinical data sources
Capecitabine [37] Capecitabine 35,000 mg/m2 8 116.13 929.04
CAPOXa [31, 35, 36] Capecitabine 28,000 mg/m2 4 410.80 1643.22
Oxaliplatin 130 mg/m2
CAPOXa [31, 35, 36] Capecitabine 28,000 mg/m2 8 410.80 3286.43
Oxaliplatin 130 mg/m2
Fluorouracil/leucovorin (bimonthly) [30, 32–34, 60] Fluorouracil 400 mg/m2 12 57.33 687.91
Fluorouracil 1200 mg/m2
Leucovorin 200 mg/m2








ST for recurrence; clinical data sources
Bevacizumab/CAPOX [69, 74] Bevacizumab 7.5 mg/kg 12 1733.60 20,803.25
CAPOX a
Bevacizumab/FOLFOX6 [69] Bevacizumab 5 mg/kg 12 1634.45 19,613.35
FOLFOX6 b










Cetuximab/FOLFOX6 [69] Cetuximab 500 mg/m2 12 2111.56 25,338.67
FOLFOX6 b
Cetuximab/FOLFOX6 [69] Cetuximab 650 mg/m2 12 2711.53 32,538.31
FOLFOX6 b
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nodal staging. Therefore, these results do not directly relate/
correspond to those obtained in the present study.
Several authors agree on using more sensitive molecu-
lar methods of LN staging in CRC, rather than GS [11, 12, 
46–49], to help identify CRC patients who are histologically 
LN-negative after a potentially curative surgical resection 
and who are nevertheless at risk of recurrence [12, 47, 48]. 
Precise pathological LN staging is critical in determining 
the most suitable treatment [50, 51]. Nevertheless, not only 
are new techniques needed to achieve better patient staging 
but also new treatments with improved outcomes, as efficacy 
observed with current chemotherapy regimens for CRC is 
limited [52].
The results of the present study relate to Spain, however 
the OSNA technique could also be incorporated in other 
countries. Further studies comparing clinical outcomes 
such as recurrence rates or overall survival between patients 
whose LNs have been analysed using the OSNA technique 
versus the GS technique would be of interest. Moreover, 
although this study reports a relevant economic benefit 
for the Spanish NHS in a scenario using OSNA, further 
pharmacoeconomic evaluations, such as cost-effectiveness 
analysis, could also help health services make informed 
decisions regarding the feasibility of introducing OSNA in 
their clinical practice.
4.1  Limitations
Pharmacoeconomic studies are subject to limitations, mainly 
due to the fact that reality ought to be simplified in order to 
elaborate the model. The present analysis assumed that the 
size of the target population remained unchanged over the 
3-year period in order to collect all costs associated with the 
incident cohort. At the time of the study, no data were avail-
able regarding the mortality rates compared between OSNA 
and GS. Furthermore, clinical data used to calculate the pro-
portion of patients with negative and positive results in the 
reference and test scenarios were taken from different stud-
ies including a sample of patients, which might differ from 
real clinical practice in Spain. However, inputs regarding the 
staging and recurrence rates of patients were obtained from 
the same study for consistency. Additionally, the proportion 
ST systemic therapy, € Euros
a Treatment regimen includes the same molecules and doses per cycle indicated for CAPOX
b Treatment regimen includes the same molecules and doses per cycle indicated for FOLFOX4
Table 2  (continued)
Molecule Dose per cycle No. of cycles 
per year
Cost per cycle (€) Annual cost (€)





Panitumumab/FOLFOX6 [72] Panitumumab 6 mg/kg 12 2140.00 25,679.95
FOLFOX6 b
Table 3  Results of the budget impact of introducing OSNA in Spanish clinical practice over a 3-year time horizon (Euros)
GS gold standard, OSNA one-step nucleic acid amplification assay, ST systemic therapy













Surgery 126,983,355 126,983,355 0.00 0.00 0.00 0.00
Staging 2,697,072 8,990,240 0.00 0.00 0.00 0.00
ST after first surgery 11,959,135 4,314,396 0.00 0.00 0.00 0.00
Follow-up 33,114,221 33,355,561 31,856,889 32,565,720 30,628,249 31,789,382
Recurrence surgery 1,691,066 1,606,289 1,658,940 1,040,519 1,626,814 1,028,025
ST after recurrence 6,266,955 5,952,781 18,585,905 11,640,994 30,623,750 19,247,325
Total cost 182,711,803 181,202,621 52,101,734 45,247,233 62,878,813 52,064,732
Budget impact 1,509,182 6,854,501 10,814,082
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of negative and positive OSNA results might be associated 
with sample bias in the study design, which was performed 
according to the actual guidelines of LN analysis and staging 
in CRC. To date, all CRC studies performed using OSNA 
have the same sample bias, resulting from using part of the 
LNs for H&E analysis and GS staging, and using the rest 
for OSNA. Consequently, metastasis might have only been 
present in part of the H&E analysis, leading to false negative 
OSNA results [17, 18, 53].
Furthermore, another limitation is in regard to data 
obtained from Rakislova et al. [18], as LNs were analysed 
using both the GS and OSNA techniques, and treated accord-
ing to the GS diagnosis. Therefore, patient outcomes remain 
unknown in the hypothetical case that patients’ treatment 
decisions would have only been based on the OSNA results. 
Hence, a randomised study is needed to obtain accurate out-
comes in those patients treated after the OSNA results had 
been reported and those treated after GS diagnosis, in order 
to assess a possible differential treatment effect depending 
on the staging diagnostic procedure performed, i.e., OSNA 
or GS. Costs related to adverse effects and adverse events 
management were not included in both interventions since 
they are the same for both OSNA and GS. Diagnosis is 
performed after tissue containing the tumour is resected 
from the patient. Therefore, patients do not undergo extra 
interventions as LN analysis is performed in the laboratory, 
with no adverse events for the patient. Thus, adverse events 
relating to diagnostic techniques for CRC have not been 
identified.
5  Conclusions
The introduction of OSNA for the management of CRC 
patients in Spanish clinical practice may represent an eco-
nomic benefit for the NHS, as well as clinical benefit for 
CRC patients. OSNA results offer higher diagnostic reli-
ability than the currently used GS techniques. The introduc-
tion of OSNA may allow more accurate staging of patients, 
which could help in avoiding unnecessary treatments with-
out affecting a patient’s prognosis (recurrence), or may pro-
vide the opportunity to receive treatment for those patients 
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Fig. 2  Tornado diagram, one-way sensitivity analysis results. Ver-
tical line indicates the total cost saving from the base case, and the 
horizontal lines indicate the shift in the range of outputs obtained by 
varying each input to a lower (black) and higher (light grey) value. 
CEA carcinoembryonic antigen, CT computed tomography, GS gold 
standard, N number of patients, OSNA one-step nucleic acid amplifi-
cation assay, ST systemic therapy, € Euros
664 S. Diaz-Mercedes et al.
Acknowledgements The authors acknowledge Clara Carrascosa for her 
technical support, and Sysmex Coorp Spain (Sant Just Desvern, Spain) 
for the technical advice and support provided.
Compliance with Ethical Standards 
Funding This work was supported by Grants from the Instituto de 
Salud Carlos III (PI17/01304), Fundación Científica de la Aso-
ciación Española Contra el Cáncer (GCB13131592CAST), Ministe-
rio de Economía y Competitividad (SAF2014-54453-R), and Agèn-
cia de Gestió d’Ajuts Universitaris i de Recerca (2017SGR653 and 
2017SGR00735), as well as by the Banc de Tumors-Biobanc Hospital 
Clinic-IDIBAPS and Xarxa de Bancs de Tumors de Catalunya (XBTC). 
CIBERehd is funded by the Instituto de Salud Carlos III. The authors 
also acknowledge the support of the CERCA Programme/Generalitat 
de Catalunya.
Author contributions MC, IAr, JMB, SD-M, IAl, and AC contributed 
to the conception and planning of the work that led to the manuscript; 
acquisition, analysis and interpretation of the data; drafting and/or criti-
cal revision of the manuscript for important intellectual content; and 
approval of the final version of the submitted manuscript. AI, AdL, 
DM, FB, IG, JAB, JC, JM, and NC contributed to the acquisition, 
analysis and interpretation of the data, and approval of the final version 
of the submitted manuscript.
Data availability statement Data are available from the authors upon 
reasonable request.
Conflict of interest Sherley Diaz-Mercedes, Ivan Archilla, Jordi 
Camps, Antonio de Lacy, Iñigo Gorostiaga, Dulce Momblan, Ainitze 
Ibarzabal, Joan Maurel, Nuria Chic, Josep Antoni Bombí, Francesc 
Balaguer, Antoni Castells, Iban Aldecoa, Josep Maria Borras and Mir-
iam Cuatrecasas declare no conflicts of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal 
A. Global cancer statistics 2018: GLOBOCAN estimates of inci-
dence and mortality worldwide for 36 cancers in 185 countries. 
CA Cancer J Clin. 2018;68(6):394–424.
Fig. 3  Two-way sensitivity analysis results. GS gold standard, OSNA one-step nucleic acid amplification assay, ST systemic therapy
665Budget Impact Analysis of Molecular LN Staging in Colorectal Carcinoma
 2. Sociedad Española de Oncología Médica (SEOM). Las Cifras del 
Cáncer en España. 2018.
 3. Globocan, International Agency for Research on Cancer. World 
Cancer Fact Sheet. GLOBOCAN. 2013 ed. Lyon: International 
Agency for Research on Cancer. http://globo can.iarc.fr/Pages /
fact_sheet s_cance r.aspx. Accessed 6 Sept 2018.
 4. Office for National Statistics. Cancer survival in England—adults 
diagnosed: 2008–2012, followed up to 2013 London: Office for 
National Statistics; 2014.
 5. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods 
LM, et al. Population-based cancer survival trends in England 
and Wales up to 2007: an assessment of the NHS cancer plan for 
England. Lancet Oncol. 2009;10(4):351–69.
 6. Pahlman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke 
P, Glimelius B. Should the benefit of adjuvant chemotherapy in 
colon cancer be re-evaluated? J Clin Oncol. 2016;34(12):1297–9.
 7. Corral J, Castells X, Molins E, Chiarello P, Borras JM, Cots F. 
Long-term costs of colorectal cancer treatment in Spain. BMC 
Health Serv Res. 2016;16:56.
 8. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, 
Borras JM, et al. Multidisciplinary rectal cancer management: 2nd 
European rectal cancer consensus conference (EURECA-CC2). 
Radiother Oncol. 2009;92(2):148–63.
 9. Compton CC. Optimal pathologic staging: defining stage II dis-
ease. Clin Cancer Res. 2007;13(22):6862s–70s.
 10. Yamamoto H, Sekimoto M, Oya M, Yamamoto N, Konishi F, 
Sasaki J, et al. OSNA-based novel molecular testing for lymph 
node metastases in colorectal cancer patients: results from a mul-
ticenter clinical performance study in Japan. Ann Surg Oncol. 
2011;18(7):1891–8.
 11. Hyslop T, Waldman SA. Molecular staging of node negative 
patients with colorectal cancer. J Cancer. 2013;4(3):193.
 12. Rahbari NN, Bork U, Motschall E, Thorlund K, Büchler MW, 
Koch M, et al. Molecular detection of tumor cells in regional 
lymph nodes is associated with disease recurrence and poor sur-
vival in node-negative colorectal cancer: a systematic review and 
meta-analysis. J Clin Oncol. 2011;30(1):60–70.
 13. Weitz J, Kienle P, Magener A, Koch M, Schrödel A, Willeke 
F, et  al. Detection of disseminated colorectal cancer cells 
in lymph nodes, blood and bone marrow. Clin Cancer Res. 
1999;5(7):1830–6.
 14. Croner RS, Geppert CI, Bader FG, Nitsche U, Spath C, Rosen-
berg R, et al. Molecular staging of lymph node-negative colon 
carcinomas by one-step nucleic acid amplification (OSNA) results 
in upstaging of a quarter of patients in a prospective, European, 
multicentre study. Br J Cancer. 2014;110(10):2544–50.
 15. Yamamoto H, Tomita N, Inomata M, Furuhata T, Miyake Y, 
Noura S, et al. OSNA-assisted molecular staging in colorectal 
cancer: a prospective multicenter trial in Japan. Ann Surg Oncol. 
2016;23(2):391–6.
 16. Vogelaar FJ, Reimers MS, van der Linden RL, van der Linden 
JC, Smit VT, Lips DJ, et al. The diagnostic value of one-step 
nucleic acid amplification (OSNA) for sentinel lymph nodes in 
colon cancer patients. Ann Surg Oncol. 2014;21(12):3924–30.
 17. Aldecoa I, Atares B, Tarragona J, Bernet L, Sardon JD, Pereda 
T, et al. Molecularly determined total tumour load in lymph 
nodes of stage I-II colon cancer patients correlates with high-
risk factors. A multicentre prospective study. Virchows Arch. 
2016;469(4):385–94.
 18. Rakislova N, Montironi C, Aldecoa I, Fernandez E, Bombi JA, 
Jimeno M, et al. Lymph node pooling: a feasible and efficient 
method of lymph node molecular staging in colorectal carcinoma. 
J Transl Med. 2017;15(1):14.
 19. Wild JB, Iqbal N, Francombe J, Papettas T, Sanders DS, Ram-
charan S. Is it time for one-step nucleic acid amplification (OSNA) 
in colorectal cancer? A systematic review and meta-analysis. Tech 
Coloproctol. 2017;21(9):693–9.
 20. National Comprehensive Cancer Network. NCCN Guidelines for 
Patients: Colon Cancer. National Comprehensive Cancer Network; 
2016, 2017. Available at: https ://www.nccn.org.
 21. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. 
Colorectal cancer. Lancet. 2005;365(9454):153–65.
 22. National Institute for Health and Care Excellence (NICE). OSNA 
for colon cancer staging. 2016. https ://www.nice.org.uk/advic e/
mib77 /resou rces/osna-for-colon -cance r-stagi ng-pdf-63499 35249 
8629. Accessed 24 July 2018.
 23. Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antunez JR, 
de Salas MS, et al. Intraoperative molecular analysis of total 
tumor load in sentinel lymph node: a new predictor of axillary 
status in early breast cancer patients. Breast Cancer Res Treat. 
2013;139(1):87–93.
 24. Peg V, Sansano I, Vieites B, Bernet L, Cano R, Córdoba A, et al. 
Role of total tumour load of sentinel lymph node on survival in 
early breast cancer patients. Breast. 2017;33:8–13.
 25. Saruta Y, Puig-Junoy J. Cost and budget impact analysis of 
an accurate intraoperative sentinel lymph node diagnosis for 
breast cancer metastasis. Appl Health Econ Health Policy. 
2016;14(3):323–35.
 26. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee 
KM, Minchin M, et al. Budget impact analysis—principles of 
good practice: report of the ISPOR 2012 Budget Impact Analysis 
Good Practice II Task Force. Value Health. 2014;17(1):5–14.
 27. Puig-Junoy J, Oliva-Moreno J, Trapero-Bertran M. Abellán-
Perpiñán JM, Brosa-Riestra M, Servei Català de la Salut (Cat-
Salut). Guia i recomanacions per a la realització i presentació 
d’avaluacions econòmiques i anàlisis d’impacte pressupostari de 
medicaments en l’àmbit del CatSalut. Barcelona: Generalitat de 
Catalunya. Departament de Salut. Servei Català de la Salut; 2014.
 28. MSSSI. Ministerio de Sanidad Servicios Sociales e Igualdad. 
Informe Anual del Sistema Nacional de Salud. 2017. https ://www.
mscbs .gob.es/estad Estud ios/estad istic as/sisIn fSanS NS/tabla sEsta 
disti cas/InfAn SNS.htm. Accessed 25 July 2018.
 29. GLOBOCAN. Estimated cancer incidence, mortality and preva-
lence worldwide in 2012. http://globo can.iarc.fr/Defau lt.aspx. 
Accessed 23 July 2018.
 30. André T, De Gramont A, Vernerey D, Chibaudel B, Bonnetain F, 
Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and 
oxaliplatin in stage II to III colon cancer: updated 10-year survival 
and outcomes according to BRAF mutation and mismatch repair 
status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–87.
 31. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb 
J, et al. Duration of adjuvant chemotherapy for stage III colon 
cancer. N Engl J Med. 2018;378(13):1177–88.
 32. Group QC. Adjuvant chemotherapy versus observation in 
patients with colorectal cancer: a randomised study. Lancet. 
2007;370(9604):2020–9.
 33. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cut-
sem E, et al. Capecitabine plus oxaliplatin compared with fluo-
rouracil and folinic acid as adjuvant therapy for stage III colon 
cancer. J Clin Oncol. 2011;29(11):1465–71.
 34. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo 
LH, Yothers G, et al. Oxaliplatin combined with weekly bolus 
fluorouracil and leucovorin as surgical adjuvant chemotherapy for 
stage II and III colon cancer: results from NSABP C-07. J Clin 
Oncol. 2007;25(16):2198–204.
 35. Shah MA, Renfro LA, Allegra CJ, André T, De Gramont A, 
Schmoll H-J, et al. Impact of patient factors on recurrence risk 
and time dependency of oxaliplatin benefit in patients with colon 
cancer: analysis from modern-era adjuvant studies in the adju-
vant colon cancer end points (ACCENT) database. J Clin Oncol. 
2016;34(8):843.
666 S. Diaz-Mercedes et al.
 36. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, 
Hickish T, et al. Adjuvant therapy with fluorouracil and oxali-
platin in stage II and elderly patients (between ages 70 and 
75 years) with colon cancer: subgroup analyses of the multi-
center international study of oxaliplatin, fluorouracil, and leuco-
vorin in the adjuvant treatment of colon cancer trial. J Clin Oncol. 
2012;30(27):3353–60.
 37. Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato 
A, et al. Capecitabine as adjuvant treatment for stage III colon 
cancer. N Engl J Med. 2005;352(26):2696–704.
 38. Cuatrecasas M. Budget impact of molecular lymph node staging 
in colorectal carcinoma. Should we invest more in diagnosis? 30th 
European Congress of Pathology. Virchows Arch. 2018;473(Suppl 
1):S1–340.
 39. Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic 
M, et al. Surgical quality and nodal ultrastaging is associated 
with long-term disease-free survival in early colorectal cancer: 
an analysis of 2 international multicenter prospective trials. Ann 
Surg. 2010;252(3):467–74 (discussion 74–76).
 40. Corral J, Borràs JM, Chiarello P, García-Alzorriz E, Macià F, Reig 
A, et al. Estimación del coste hospitalario del cáncer colorrectal 
en Cataluña. Gaceta Sanitaria. 2015;29(6):437–44.
 41. Weixler B, Warschkow R, Guller U, Zettl A, von Holzen U, 
Schmied BM, et al. Isolated tumor cells in stage I & II colon can-
cer patients are associated with significantly worse disease-free 
and overall survival. BMC Cancer. 2016;16:106.
 42. Consejo General de Colegios Oficiales de Farmacéuticos. Botplus 
portalfarma. https ://botpl usweb .porta lfarm a.com/. Accessed 13 
July 2017.
 43. Instituto Nacional de Estadística (INE). http://www.ine.es/. 
Accessed 13 July 2017.
 44. Oblikue Consulting S.L. Base de datos de costes sanitarios y 
ratios coste-efectividad españoles: eSalud. 2018. http://www.oblik 
ue.com/bddco stes/. Accessed 3 Sept 2018.
 45. MSSSI. Ministerio de Sanidad Servicios Sociales e Igualdad. 
Gasto Sanitario. Informe Anual del Sistema Nacional de Salud. 
2016. https ://www.mscbs .gob.es/estad Estud ios/estad istic as/sisIn 
fSanS NS/tabla sEsta disti cas/InfAn ualSN S2016 /7Gast _Sanit .pdf. 
Accessed 3 Sept 2018.
 46. Sirop S, Kanaan M, Korant A, Wiese D, Eilender D, Nagpal S, 
et al. Detection and prognostic impact of micrometastasis in colo-
rectal cancer. J Surg Oncol. 2011;103(6):534–7.
 47. Sloothaak D, Sahami S, van der Zaag-Loonen HV, Van der Zaag 
E, Tanis P, Bemelman W, et al. The prognostic value of microme-
tastases and isolated tumour cells in histologically negative lymph 
nodes of patients with colorectal cancer: a systematic review and 
meta-analysis. Eur J Surg Oncol. 2014;40(3):263–9.
 48. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic 
effect of micrometastases in previously staged lymph node nega-
tive (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 
2006;13(11):1386–92.
 49. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult 
lymph node disease in colorectal cancer patients clinically 
significant?: a review of the relevant literature. J Mol Diagn. 
2007;9(5):563–71.
 50. Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius 
B, Haustermans K, et  al. ESMO Consensus Guidelines for 
management of patients with colon and rectal cancer: a per-
sonalized approach to clinical decision making. Ann Oncol. 
2012;23(10):2479–516.
 51. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, 
Haq A, et al. Improving outcomes in colorectal cancer: where do 
we go from here? Eur J Cancer. 2013;49(11):2476–85.
 52. Sociedad Española de Oncología Médica. Información sobre 
el cáncer. Cáncer de colon y recto. https ://www.seom.org/es/
info-sobre -el-cance r/colon -recto ?start =8#conte nt. Accessed 13 
July 2018.
 53. Aldecoa I, Montironi C, Planell N, Pellise M, Fernandez-Espar-
rach G, Gines A, et al. Endoscopic tattooing of early colon car-
cinoma enhances detection of lymph nodes most prone to harbor 
tumor burden. Surg Endosc. 2017;31(2):723–33.
 54. Galceran J, Ameijide A, Carulla M, Mateos A, Quirós J, Rojas 
D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 
2017;19(7):799–825.
 55. Li Destri G, Di Carlo I, Scilletta R, Scilletta B, Puleo S. Colorectal 
cancer and lymph nodes: the obsession with the number 12. World 
J Gastroenterol. 2014;20(8):1951–60.
 56. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre 
T, et al. Evidence for cure by adjuvant therapy in colon cancer: 
observations based on individual patient data from 20,898 patients 
on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.
 57. MSSSI. Ministerio de Sanidad Servicios Sociales e Igualdad. La 
hospitalización en el Sistema Nacional de Salud CMBD—Reg-
istro de altas. Informe resumen 2010. Información y Estadísticas 
Sanitarias. 2012. https ://www.mscbs .gob.es/estad Estud ios/estad 
istic as/docs/Hospi taliz acion _SNS_CMBD_Infor me201 0.pdf. 
Accessed 13 July 2017.
 58. Sysmex Spain. 2018. https ://www.sysme x.es/. Accessed 3 Sept 
2018.
 59. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, 
Lotz JP, et al. CPT-11 (irinotecan) addition to bimonthly, high-
dose leucovorin and bolus and continuous-infusion 5-fluorouracil 
(FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. 
Eur J Cancer. 1999;35(9):1343–7.
 60. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cas-
sidy J, et al. Leucovorin and fluorouracil with or without oxalipl-
atin as first-line treatment in advanced colorectal cancer. J Clin 
Oncol. 2000;18(16):2938–47.
 61. Jager E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, 
et al. Weekly high-dose leucovorin versus low-dose leucovorin 
combined with fluorouracil in advanced colorectal cancer: results 
of a randomized multicenter trial. Study Group for Palliative 
Treatment of Metastatic Colorectal Cancer Study Protocol 1. J 
Clin Oncol. 1996;14(8):2274–9.
 62. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Car-
ola E, Gilles V, et al. Evaluation of oxaliplatin dose intensity 
in bimonthly leucovorin and 48-hour 5-fluorouracil continuous 
infusion regimens (FOLFOX) in pretreated metastatic colorectal 
cancer. Oncology Multidisciplinary Research Group (GERCOR). 
Ann Oncol. 2000;11(11):1477–83.
 63. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, 
Boyer M, et al. Oral capecitabine compared with intravenous 
fluorouracil plus leucovorin in patients with metastatic colo-
rectal cancer: results of a large phase III study. J Clin Oncol. 
2001;19(21):4097–106.
 64. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, 
Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil 
as postoperative adjuvant therapy for primary colon cancer: results 
from National Surgical Adjuvant Breast and Bowel Project proto-
col C-03. J Clin Oncol. 1993;11(10):1879–87.
 65. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, et al. 
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal 
cancer: a new survival standard. Oncologist. 2001;6(1):81–91.
 66. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, 
Christophylakis C, Kalykaki A, et al. Front-line bevacizumab in 
combination with oxaliplatin, leucovorin and 5-fluorouracil (FOL-
FOX) in patients with metastatic colorectal cancer: a multicenter 
phase II study. BMC Cancer. 2007;7:91.
 67. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery 
M, et al. Randomized, controlled trial of irinotecan plus infu-
sional, bolus, or oral fluoropyrimidines in first-line treatment of 
667Budget Impact Analysis of Molecular LN Staging in Colorectal Carcinoma
metastatic colorectal cancer: results from the BICC-C Study. J 
Clin Oncol. 2007;25(30):4779–86.
 68. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Sal-
vatore L, et  al. Initial therapy with FOLFOXIRI and beva-
cizumab for metastatic colorectal cancer. N Engl J Med. 
2014;371(17):1609–18.
 69. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Mey-
erhardt JA, et al. Effect of first-line chemotherapy combined with 
cetuximab or bevacizumab on overall survival in patients with 
KRAS wild-type advanced or metastatic colorectal cancer: a ran-
domized clinical trial. JAMA. 2017;317(23):2392–401.
 70. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-
Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus 
FOLFIRI plus bevacizumab as first-line treatment for patients 
with metastatic colorectal cancer (FIRE-3): a randomised, open-
label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.
 71. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko 
Y, et al. Randomized phase III study of panitumumab with fluo-
rouracil, leucovorin, and irinotecan (FOLFIRI) compared with 
FOLFIRI alone as second-line treatment in patients with meta-
static colorectal cancer. J Clin Oncol. 2010;28(31):4706–13.
 72. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel 
M, et al. Randomized, phase III trial of panitumumab with infu-
sional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus 
FOLFOX4 alone as first-line treatment in patients with previously 
untreated metastatic colorectal cancer: the PRIME study. J Clin 
Oncol. 2010;28(31):4697–705.
 73. La hospitalización en el Sistema Nacional de Salud CMBD—Reg-
istro de altas. Informe resumen 2010. Información y estadísticas 
sanitarias 2012 [online database]. https ://www.mscbs .gob.es/estad 
Estud ios/estad istic as/docs/Hospi taliz acion _SNS_CMBD_Infor 
me201 0.pdf. Accessed 8 Jan 2018.
 74. ICO. Institut Català d’Oncologia. Informe per a la comissió de 
farmàcia i terapèutica ICO i la sub-comissió de càncer de l’ICS. 
Cetuximab y bevacizumab. Cáncer colorrectal metastásico 
(CCRm) 1ª línea. 2016.
 75. ICO. Institut Català d’Oncologia. Informe per a la comissió de 
farmàcia i terapèutica ICO. Panitumumab vs cetuximab. Càncer 
colorectal metastàsic (CCRm). 2010.
Affiliations
Sherley Diaz‑Mercedes1  · Ivan Archilla1 · Jordi Camps2,8 · Antonio de Lacy3 · Iñigo Gorostiaga4 · Dulce Momblan3 · 
Ainitze Ibarzabal3 · Joan Maurel5 · Nuria Chic5 · Josep Antoni Bombí1 · Francesc Balaguer2,8 · Antoni Castells2,8  · 
Iban Aldecoa1,6  · Josep Maria Borras7 · Miriam Cuatrecasas1,4,8 
1 Pathology Department-Center of Biomedical Diagnosis 
(CDB), Hospital Clínic, University of Barcelona, Villarroel 
170, 08036 Barcelona, Spain
2 Gastroenterology Department, Hospital Clinic, University 
of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
3 Surgical Department, Hospital Clinic, Barcelona, Spain
4 Pathology Department, Araba University Hospital, 
Vitoria-Gasteiz, Spain
5 Medical Oncology Department, Hospital Clinic of Barcelona, 
Translational Genomics and Targeted Therapeutics in Solid 
Tumors Group, IDIBAPS, University of Barcelona, 
Barcelona, Spain
6 Neurological Tissue Bank of the Biobank 
Clinic-IDIBAPS-XBTC, Hospital Clinic, Barcelona, Spain
7 Department of Clinical Sciences and Bellvitge Biomedical 
Research Institute (IDIBELL), Universitat de Barcelona, 
Barcelona, Spain
8 CIBERehd and Banc de Tumors-Biobanc 
Clinic-IDIBAPS-XBTC, Hospital Clinic, Barcelona, Spain
